SCHEMBL720995

SCHEMBL720995

CCOC(=O)CCN(C)C(=O)c1ccc(NC(c2c(C)oc3cc(OC)ccc23)C2CCCCC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.39
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
POLB P06746 2/20 0.36
ESR1 P03372 1/20 0.36
HPGD P15428 1/20 0.36
NR4A1 P22736 1/20 0.36
APEX1 P27695 1/20 0.36
ESR2 Q92731 1/20 0.36
CTDSP1 Q9GZU7 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TAS1R3 Q7RTX0 1/20 0.36
TAS1R1 Q7RTX1 1/20 0.36
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
IDH1 O75874 1/20 0.34
TP53 P04637 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719471 0.92 ALDH1A1 (0.38) ALDH1A1KDM4EPOLBESR1HPGD
SCHEMBL721022 0.86 CYP2C19 (0.38) ALDH1A1KDM4EPOLBESR1HPGD
SCHEMBL716683 0.85 NPC1 (0.43) TSHRALDH1A1KDM4EPOLBL3MBTL1
SCHEMBL3403651 0.84 TSHR (0.39) TSHRALDH1A1KDM4EPOLBHPGD
SCHEMBL716783 0.82 KMT2A (0.39) TSHRALDH1A1KDM4EPOLBHPGD
SCHEMBL717996 0.82 TSHR (0.38) TSHRALDH1A1KDM4EPOLBHPGD
SCHEMBL718485 0.80 PIK3CB (0.35) ALDH1A1KDM4EHPGDTDP1L3MBTL1
SCHEMBL718999 0.78 NPC1 (0.36) TSHRALDH1A1KMT2AMEN1NPC1
SCHEMBL721554 0.78 IDH1 (0.42) KMT2AMEN1IDH1TP53MAPT
SCHEMBL718427 0.78 KMT2A (0.35) TSHRALDH1A1KDM4EHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP TSHR 1555/4885ALDH1A1 504/4885KDM4E 1907/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP TSHR 1555/4885ALDH1A1 504/4885KDM4E 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.